Fig. 1From: Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiencyStudy design. aWithdrawal phase included a variably timed 4-week placebo period and a 4-week period of setmelanotide treatmentBack to article page